MedTrace Logo

TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine

NCT04671459 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-06-28

No results posted yet for this study

Summary

All patients will receive TTFields therapy and additionally Stereotactic Radiosurgery . Radiosurgery will be based on MRI and FET-PET or MRI alone. Addition of FET-PET will be preferred option.

Conditions

Interventions

COMBINATION_PRODUCT

TTFields and SRS

SRS procedure will be delivered within 7 days after start of TTFields therapy . A 5-day SRS regimen is allowed. TTFields should be interrupted in time of SRS and start immediately after.

Sponsors & Collaborators

  • NovoCure GmbH

    collaborator INDUSTRY

  • Prof. Franciszek Lukaszczyk Memorial Oncology Center

    lead OTHER

Principal Investigators

  • Maciej Harat, MD PhD · Prof. Franciszek Lukaszczyk Memorial Oncology Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-26
Primary Completion
2023-07-20
Completion
2024-12-09

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04671459 on ClinicalTrials.gov